Michelle Gilson
Stock Analyst at Morgan Stanley
(1.12)
# 3,757
Out of 5,182 analysts
32
Total ratings
34.48%
Success rate
-6.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Overweight | $20 → $24 | $10.37 | +131.44% | 5 | Feb 24, 2026 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $46.06 | -34.87% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.10 | +448.39% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $229.27 | -14.51% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $40.50 | +11.11% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $34.03 | +123.33% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $53.18 | +71.12% | 12 | Mar 1, 2021 |
Vir Biotechnology
Feb 24, 2026
Maintains: Overweight
Price Target: $20 → $24
Current: $10.37
Upside: +131.44%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $46.06
Upside: -34.87%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.10
Upside: +448.39%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $229.27
Upside: -14.51%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $40.50
Upside: +11.11%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $34.03
Upside: +123.33%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $53.18
Upside: +71.12%